Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2009-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.108.146647PMID 19001154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

  2007cited by this paper
• SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

  2007cited by this paper
• Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans

  2007cited by this paper
• Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans

  2007cited by this paper
• In Vitro–In Vivo Correlation of Hepatobiliary Drug Clearance in Humans

  2007cited by this paper
• Transporters as a determinant of drug clearance and tissue distribution.

  2006cited by this paper
• Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy

  2006cited by this paper
• SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

  2006cited by this paper
• Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril

  2006cited by this paper
• Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

  2006cited by this paper
• A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

  2006cited by this paper
• A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

  2004cited by this paper
• Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

  2003cited by this paper
• Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A

  2003cited by this paper
• Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions.

  2002cited by this paper
• Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

  2001cited by this paper
• Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.

  2001cited by this paper
• Primary active transport of organic anions on bile canalicular membrane in humans.

  1999influential reference
• Primary active transport of organic anions on bile canalicular membrane in humans.

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human.

  1998cited by this paper
• Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.

  1997cited by this paper
• Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

  1997influential reference
• Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors

  1997cited by this paper
• Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats.

  1996cited by this paper
• Uptake Is the Rate-limiting Step in the Overall Hepatic Elimination of Pravastatin at Steady-state in Rats

  1996influential reference
• Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system.

  1996influential reference
• Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats.

  1996influential reference
• Evaluation of the Uptake of Pravastatin by Perfused Rat Liver and Primary Cultured Rat Hepatocytes

  1995cited by this paper
• Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125

  1994cited by this paper
• Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium.

  1993cited by this paper
• Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

  1993cited by this paper
• Comparison of the Hepatic Uptake Clearances of Fifteen Drugs with a Wide Range of Membrane Permeabilities in Isolated Rat Hepatocytes and Perfused Rat Livers

  1993cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys

  1992influential reference
• Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.

  1990influential reference
• Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model

  1986cited by this paper
• Goodman & Gilman's The Pharmacological Basis of Therapeutics

  1985cited by this paper
• Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats

  1985cited by this paper
• A pharmacokinetic analysis program (multi) for microcomputer.

  1981cited by this paper
• Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.

  1977cited by this paper

• Modeling Metabolite Kinetics with a Partial Differential Equation-Based Hepatic Sinusoidal Model and MALDI-Mass Spectrometry Imaging of Verapamil and Its Metabolites.

  2026cites this paper
• Development of Physiologically Based Liver Distribution Model that Incorporates Intracellular Lipid Partitioning and Binding to Fatty Acid Binding Protein 1 (FABP1)

  2026cites this paper
• Estimation and Validation of an Effective Ergothioneine Dose for Improved Sleep Quality Using Physiologically Based Pharmacokinetic Model

  2025cites this paper
• Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK model with enterohepatic circulation.

  2025cites this paper
• The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling

  2024influential citation
• Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine

  2024cites this paper
• After 50 Years of Hepatic Clearance Models, Where Should We Go from Here? Improvements and Implications for Physiologically Based Pharmacokinetic Modeling

  2024cites this paper
• Membrane transporters in drug development and as determinants of precision medicine

  2024cites this paper
• Albumin-bound kynurenic acid is an appropriate endogenous biomarker for assessment of the renal tubular OATs-MRP4 channel

  2023cites this paper
• Exploring the Pharmacokinetic Mysteries of the Liver: Application of Series Compartment Models of Hepatic Elimination

  2023cites this paper
• [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].

  2023cites this paper
• Evaluation of the non-linearity of NA808 in liver not reflected in plasma using a rat pharmacokinetic study and PBPK modelling

  2023cites this paper
• Utility of Minimal Physiologically Based Pharmacokinetic Models for Assessing Fractional Distribution, Oral Absorption, and Series-Compartment Models of Hepatic Clearance

  2023cites this paper
• Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil.

  2023cites this paper
• Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modelling

  2023cites this paper
• Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

  2022cites this paper
• Pharmacogenomic mechanisms of drug toxicity

  2022cites this paper
• A myth of the well-stirred model: is the well-stirred model good for high clearance drugs?

  2022cites this paper
• Analysis of Time-Dependent Pharmacokinetics Using In Vitro–In Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling

  2022cites this paper
• Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.

  2022cites this paper
• Assessing Liver-to-Plasma Partition Coefficients and In Silico Calculation Methods: When Does the Hepatic Model Matter in PBPK?

  2022cites this paper
• Drug-drug interactions

  2022cites this paper
• The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans.

  2022cites this paper
• Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver.

  2022cites this paper
• Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs

  2022cites this paper
• Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood–Brain Barrier

  2022cites this paper
• Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs

  2022cites this paper
• Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

  2022cites this paper
• Advancing Estimation of Hepatobiliary Clearances in Physiologically Based Pharmacokinetic Models of Rosuvastatin Using Human Hepatic Concentrations

  2021cites this paper
• Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance

  2021cites this paper
• Preliminary Flow Modeling by Hybrid Automata Alternating Continuous Reaction and Discrete Transit for Pharmacokinetics

  2021influential citation
• Organic Anion–Transporting Polypeptide 1B1/1B3–Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro–In Vivo Evaluation in Cynomolgus Monkey

  2021cites this paper
• OATP1B1/1B3-mediated hepatic uptake determines the pharmacokinetics of large lipophilic acids: In vitro–in vivo evaluation in cynomolgus monkey

  2021cites this paper
• Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches

  2021cites this paper
• Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data

  2021cites this paper
• Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats

  2021cites this paper
• Quantitative Analysis of Intracellular Drug Concentrations in Hepatocytes

  2021cites this paper
• Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity

  2021cites this paper
• Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins

  2021cites this paper
• Application of a PBPK Model Incorporating the Interplay Between Transporters and Drug‐Metabolizing Enzymes for the Precise Prediction of Drug Toxicity

  2021cites this paper
• Hepatic transporter‐mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory recommendations

  2021cites this paper
• Impact of Plasma Protein Binding in Drug Clearance Prediction: A Database Analysis of Published Studies and Implications for In Vitro-In Vivo Extrapolation

  2020cites this paper
• Transporter–enzyme interplay and the hepatic drug clearance: what have we learned so far?

  2020cites this paper
• Cluster Gauss–Newton method

  2020cites this paper
• Use of imaging to assess the activity of hepatic transporters

  2020cites this paper
• Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes

  2020cites this paper
• Effect of Human Plasma on Hepatic Uptake of Organic Anion–Transporting Polypeptide 1B Substrates: Studies Using Transfected Cells and Primary Human Hepatocytes

  2020cites this paper
• Role of transporters in drug disposition and drug-drug interactions

  2020cites this paper
• Prediction of Transporter-Mediated Drug-Drug Interactions and Phenotyping of Hepatobiliary Transporters Involved in the Clearance of E7766, a Novel Macrocycle-Bridged Dinucleotide

  2020cites this paper
• In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation

  2020cites this paper
• Improved prediction of the drug-drug interactions of pemafibrate caused by cyclosporine A and rifampicin via PBPK modeling: Consideration of the albumin-mediated hepatic uptake of pemafibrate and inhibition constants with preincubation against OATP1B.

  2020cites this paper
• Comparison of In Vitro to In Vivo Extrapolation Approaches for Predicting Transporter-Mediated Hepatic Uptake Clearance Using Suspended Rat Hepatocytes

  2020cites this paper
• A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats

  2020cites this paper
• Assessing OATP1B1- and OATP1B3-mediated drug-drug interaction potential of vemurafenib using R-value and physiologically based pharmacokinetic models.

  2020cites this paper
• Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes.

  2020cites this paper
• Intestinal drug transporters in pathological states: an overview

  2020cites this paper
• Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2

  2019cites this paper
• Improvements for the in Vitro to in Vivo Extrapolation of Hepatic Clearance

  2019cites this paper
• Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters.

  2019cites this paper
• Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities

  2019cites this paper
• Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.

  2019cites this paper
• A 3D brain unit model to further improve prediction of local drug distribution within the brain

  2019cites this paper
• Evaluation of [18F]pitavastatin as a positron emission tomography tracer for in vivo organic transporter polypeptide function.

  2019cites this paper
• Mechanistic modelling of in vitro transporter processes to improve drug-drug interaction predictions

  2019cites this paper
• Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease

  2019cites this paper
• Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation

  2019cites this paper
• Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver

  2019cites this paper
• Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.

  2019cites this paper
• Changes in Organic Anion Transporting Polypeptide Uptake in HEK293 Overexpressing Cells in the Presence and Absence of Human Plasma

  2019cites this paper
• ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors

  2019cites this paper
• Current trends in drug metabolism and pharmacokinetics

  2019cites this paper
• Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects

  2019cites this paper
• PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

  2019cites this paper
• Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver

  2019cites this paper
• Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships

  2019cites this paper
• Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens

  2019cites this paper
• Physiologically‐Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine

  2019influential citation
• Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity.

  2019cites this paper
• Relationship of MATE1 Inhibition and Cytotoxicity in Nephrotoxicity: Application for Safety Evaluation in Early Drug Discovery.

  2019cites this paper
• Prediction of Metabolite‐to‐Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model

  2019cites this paper
• Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling.

  2019cites this paper
• Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype‐Guided Dosing of Tamoxifen

  2018cites this paper
• Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro

  2018cites this paper
• Discussions on the hepatic well‐stirred model: Re‐derivation from the dispersion model and re‐analysis of the lidocaine data

  2018cites this paper
• In vivo hepatic clearance of lipophilic drugs predicted by in vitro uptake data into cryopreserved hepatocytes suspended in sera of rats, guinea pigs, monkeys and humans

  2018cites this paper
• Therapeutic Roles of Statins in Gynecology and Obstetrics: The Current Evidence

  2018cites this paper
• A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models

  2018cites this paper
• Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics

  2018cites this paper
• Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example

  2018cites this paper
• A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects

  2018cites this paper
• Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

  2018cites this paper
• Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling

  2018cites this paper
• Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling

  2018cites this paper
• Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics

  2018cites this paper
• Effect of inhalation exposure to toluene on the activity of organic anion transporting polypeptide (Oatp) using pravastatin as a probe drug in rats

  2018cites this paper
• Transporter‐Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate

  2018cites this paper
• Genomics and Drug Transporters and Application in Drug Discovery, Delivery, and Development

  2018cites this paper
• Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes.

  2018cites this paper
• Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

  2018cites this paper